Gene therapy outfit emerges from stealth with big ambitions. First stop — CAR-T
There’s a new player in the gene therapy space in Boston.
Backed by science out of Stanford and MIT, the small outfit has big dreams, big ambitions, and is centered on trying to turn ex vivo gene therapy into in vivo. However, it’s starting with looking to redefine CAR-T.
Kelonia Therapeutics, backed by VCs such as Horizons Ventures and Venrock, officially launched Thursday after being in stealth for a little over a year, and has a bit of a cash stash thanks to $50 million from a Series A. President and CSO Kevin Friedman told Endpoints News that the biotech has enough runway to “progress us quite a ways toward the clinic” without giving an exact timeframe.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.